Milbank LLP advised the financing sources in connection with a $2.00 billion US Dollar denominated term loan facility, €1.250 billion Euro denominated term loan facility and $2.06 billion multi-currency revolving credit facility for Grifols, S.A. (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) and its subsidiaries (“Grifols”), a leading global producer of plasma medicines.
In an April 14, 2026 press release, Grifols noted that “[t]he transaction enhances the company’s financial flexibility, extends its debt maturity profile, and reinforces its liquidity position.” With the proceeds of this financing, Grifols was able to address all of its debt maturing prior to October 2028.
The Milbank team was led by New York-based Global Leveraged Finance partners Marcus Dougherty and Meir Hornung, together with special counsel Chris Hahm and associates Nick Morgan, Andrew Mavers and Mark Freeman.
